On 25 June Professor Louise Emmet will make an oral presentation...

On 25 June Professor Louise Emmet will make an oral presentation of LuPIN data to the SNMMI annual meeting in California.  We already know from the abstract that LuPSMA + Veyonda achieved a 75% response at 800 mg after two shots per patient.  Graham Kelly will attend the presentation.

I am also looking forward to data from the 1200 mg expansion-cohort in the DAART-1 trial, together with a read-out on the durability of responses to treatment at lower doses, which should be known in late July/early August IIRC.  It is quite remarkable, in my opinion, that DARRT-type therapy typically takes just two weeks; does not require admission to a hospital; is safe to use; and can be repeated if required..

The latest corporate presentation makes a number of references to STING agonists, so I thought I would do some research…

It appears that STING activation increases the likelihood of abscopal responses, which explains why at least five companies have a STING agonist undergoing clinical trials.  Of these, Merck, Aduro, Codiac and Synlogic compounds need to be injected directly into a tumour, with poor results so far. Noxopharm is the fifth company, with a critical difference: Veyonda is the only STING agonist in clinical trials that travels around the body.

GSK thinks this is the key to success.  See https://www.marketscreener.com/GLAX...ist-could-overcome-delivery-hurdles-27569305/